Novartis says, Daptomycin (Cubicin) achieves clinical cure rates of 72% in sepsis caused by Staphylococcus aureus and of 85% in sepsis caused by Staphylococcus epidermidis. Also says that high-dose daptomycin is also safe and tolerable, according to posters presented at the 22nd European Congress of Clinical Microbiology and Infectious Diseases.
For the analysis of daptomycin in sepsis, data were collected from 2006 to 2011. Demographic and clinical data were drawn from patients in Europe, Russia, Latin America, and India. For study inclusion, patients had to have sepsis as the primary infection, had to have received at least 1 dose of daptomycin, and had to have had more than 30 days of follow-up.
All 302 patients had significant underlying disease, most commonly cardiovascular (55%) and renal disease (23.8%).